Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 RA + SOC in Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
NCT07627191Phase 1Recruiting
- Sponsor
- University of Arizona
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of semaglutide in pancreatic cancer (PC), colorectal cancer (CRC) and hepatocellular carcinoma (HCC) (3 arms), sponsored by University of Arizona. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 6 months. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07627191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07627191.